发布求助
文献互助 智能选刊 最新文献

Trends in Immunotherapy最新文献

筛选
英文 中文
Pretibial myxedema exhibiting prominent asymmetrical manifestations 胫前黏液性水肿表现出明显的不对称表现
Trends in Immunotherapy Pub Date : 2022-05-12 DOI: 10.24294/ti.v6.i1.1423
Tomoya Sawada, A. Otsuka, K. Tsujioka
{"title":"Pretibial myxedema exhibiting prominent asymmetrical manifestations","authors":"Tomoya Sawada, A. Otsuka, K. Tsujioka","doi":"10.24294/ti.v6.i1.1423","DOIUrl":"https://doi.org/10.24294/ti.v6.i1.1423","url":null,"abstract":"Pretibial myxedema (PTM) is an uncommon cutaneous manifestation of Graves’ disease. A 62-year-old obese Japanese man treated for Graves’ disease presented with nodular lesions symmetrically on both pretibial areas. Systemic corticosteroid therapy targeted against simultaneously developing severe Graves’ ophthalmopathy almost completely cleared his skin symptoms. About ten years later, edema of both lower legs recurred, and the right lower leg showed an elephantiasis-like condition with nodules. However, the left leg had less edema and only a few nodular lesions. The skin lesions gradually improved with oral prednisolone. We speculate that our patient’s habit of lying on the right side of the body induced prominent asymmetry of skin lesions by pooling some immune mediators.","PeriodicalId":401129,"journal":{"name":"Trends in Immunotherapy","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129256965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Topical potent corticosteroids and R-CDOP improved mycosis fungoides after 20 years treatment as tinea corporis 局部强效皮质类固醇和R-CDOP可改善作为体癣治疗20年后的蕈样真菌病
Trends in Immunotherapy Pub Date : 2022-01-24 DOI: 10.24294/ti.v6.i1.1398
C. T. H. Nguyen, H. T. Nguyen, G. Tran, H. Ngo, T. Van
{"title":"Topical potent corticosteroids and R-CDOP improved mycosis fungoides after 20 years treatment as tinea corporis","authors":"C. T. H. Nguyen, H. T. Nguyen, G. Tran, H. Ngo, T. Van","doi":"10.24294/ti.v6.i1.1398","DOIUrl":"https://doi.org/10.24294/ti.v6.i1.1398","url":null,"abstract":"A 62-year-old woman reported with progressive pruritus rash that persisted on her buttocks and extremities for a duration of twenty years. She was initially diagnosed with tinea corporis but then the morphological and histological features were consistent with MF. As MF is considered as a “great imitator”, it is important to emphasize that cutaneous characteristics, skin biopsy, histology, and immunohistology may need to be performed in patients with chronic dermatoses resistant to treatment to rule out the underlying malignancy.","PeriodicalId":401129,"journal":{"name":"Trends in Immunotherapy","volume":"53 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127274963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune-related adverse events caused by combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab for lung cancer 免疫检查点抑制剂联合纳武单抗和伊匹单抗治疗肺癌引起的免疫相关不良事件
Trends in Immunotherapy Pub Date : 2022-01-14 DOI: 10.24294/ti.v6.i1.1386
T. Nomizo, Haruka Yamamoto, T. Murayama, H. Fukata, Yasukiyo Nakamura, Mami Sonomura, A. Okuno, Naoki Kanda, C. Watanabe, H. Kita
{"title":"Immune-related adverse events caused by combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab for lung cancer","authors":"T. Nomizo, Haruka Yamamoto, T. Murayama, H. Fukata, Yasukiyo Nakamura, Mami Sonomura, A. Okuno, Naoki Kanda, C. Watanabe, H. Kita","doi":"10.24294/ti.v6.i1.1386","DOIUrl":"https://doi.org/10.24294/ti.v6.i1.1386","url":null,"abstract":"It has been less than a decade since immune checkpoint inhibitors became the mainstay of lung cancer treatment, and 2020 saw the advent of the era of complex immune checkpoint inhibitors. Although clinical trials have shown that the therapeutic effects of complex immune checkpoint inhibitors are favorable, they are associated with an increase in adverse events. The use of combined immune checkpoint inhibitors in clinical practice has progressed slowly, and the frequency and types of adverse events they cause remain unclear. Here we report the adverse events of six patients with lung cancer treated with regimens containing nivolumab and ipilimumab in 2021. Four of the six patients had grade 3 or higher adverse events, including one patient with lung injury and one patient with skin injury, both of whom died. The timing and nature of the adverse events were difficult to predict.","PeriodicalId":401129,"journal":{"name":"Trends in Immunotherapy","volume":"37 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131628661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Durable complete response to combination nivolumab and ipilimumab in metastatic renal cell carcinoma 纳武单抗和伊匹单抗联合治疗转移性肾细胞癌的持久完全缓解
Trends in Immunotherapy Pub Date : 2022-01-14 DOI: 10.24294/ti.v6.i1.1387
K. Takayasu, K. Muguruma, H. Kinoshita
{"title":"Durable complete response to combination nivolumab and ipilimumab in metastatic renal cell carcinoma","authors":"K. Takayasu, K. Muguruma, H. Kinoshita","doi":"10.24294/ti.v6.i1.1387","DOIUrl":"https://doi.org/10.24294/ti.v6.i1.1387","url":null,"abstract":"Immune checkpoint inhibitors, which promote or suppress the anti-tumor immune response, are becoming the mainstay of cancer treatment. In 2018, CheckMate 214 study showed a higher response rate with ipilimumab and nivolumab combination therapy compared to conventional therapy for advanced renal cell carcinoma. We report a case of complete response and durable response for two years to ipilimumab and nivolumab combination therapy in a patient with postoperative renal cancer recurrence that caused immune-related adverse events such as interstitial pneumonia and hepatotoxicity.","PeriodicalId":401129,"journal":{"name":"Trends in Immunotherapy","volume":"77 1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128368081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Initiatives for immune-related adverse events by the outpatient pharmacist clinic 门诊药剂师诊所免疫相关不良事件的倡议
Trends in Immunotherapy Pub Date : 2022-01-10 DOI: 10.24294/ti.v6.i1.1385
K. Hamatake, Kazuaki Kojima
{"title":"Initiatives for immune-related adverse events by the outpatient pharmacist clinic","authors":"K. Hamatake, Kazuaki Kojima","doi":"10.24294/ti.v6.i1.1385","DOIUrl":"https://doi.org/10.24294/ti.v6.i1.1385","url":null,"abstract":"Early detection is the key in managing side effects because immune-related adverse events (irAEs) are becoming more serious, and their onset time differs. In our hospital, we conducted an outpatient pharmacist clinic for early detection of irAEs by self-care practice for the cases of immune checkpoint inhibitor administration. As a result of a retrospective survey of 207 cases, the percentage of irAEs found by pharmacist’s suggestion of the outpatient pharmacist clinic increased over time, and a high detection ratio was obtained even for irAEs with a late onset time. The incidence of serious irAEs was higher than that in the immediate post-marketing surveillance, and different factors were considered. Although there were some problems, the outpatient pharmacist clinic had a certain effect.","PeriodicalId":401129,"journal":{"name":"Trends in Immunotherapy","volume":"51 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121921046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Combined immunotherapy and countermeasures for immune-related adverse events 免疫相关不良事件的联合免疫治疗及对策
Trends in Immunotherapy Pub Date : 2022-01-10 DOI: 10.24294/ti.v6.i1.1384
H. Kita
{"title":"Combined immunotherapy and countermeasures for immune-related adverse events","authors":"H. Kita","doi":"10.24294/ti.v6.i1.1384","DOIUrl":"https://doi.org/10.24294/ti.v6.i1.1384","url":null,"abstract":"","PeriodicalId":401129,"journal":{"name":"Trends in Immunotherapy","volume":"31 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122356489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Daily intake of Citrus jabara fruit peel powder (Japanese Patent No. 5,323,127) improves allergy-like symptoms: A randomized double-blind parallel-group comparative study 每日摄入贾巴拉柑橘果皮粉(日本专利号5,323,127)改善过敏样症状:一项随机双盲平行组比较研究
Trends in Immunotherapy Pub Date : 2021-12-31 DOI: 10.24294/ti.v5.i2.1390
S. Azuma, Y. Murakami, M. Taniguchi, K. Baba, T. Mima, K. Nakamura
{"title":"Daily intake of Citrus jabara fruit peel powder (Japanese Patent No. 5,323,127) improves allergy-like symptoms: A randomized double-blind parallel-group comparative study","authors":"S. Azuma, Y. Murakami, M. Taniguchi, K. Baba, T. Mima, K. Nakamura","doi":"10.24294/ti.v5.i2.1390","DOIUrl":"https://doi.org/10.24294/ti.v5.i2.1390","url":null,"abstract":"Citrus jabara (CJ) is a rare citrus fruit that used to grow naturally only in the southern part of the Kii Peninsula in Japan. Human intervention studies with oral intake of CJ fruit have shown its anti-allergic effects, but the testing method was a pre-post comparison study. In this study, we conducted a randomized, double-blind, parallel-group interventional study to evaluate the volume-dependent effects of oral intake of CJ fruit peel powder (Japanese Patent No. 5,323,127) on nasal and eye allergy-like symptoms. Ninety healthy adults were allocated to three groups and given test foods containing 1,000, 500, and 0 mg of CJ peel powder, with one packet per day for 4 weeks. After excluding those who dropped out or deviated from the study protocol, 73 were included in the efficacy analysis and 86 in the safety analysis. The high-dose group (1,000 mg/day) was significantly lower than the placebo group in the scores of “nasal and eye symptoms” at week 4, and “blocked nose” at weeks 2 and 4 in the evaluation of question I of Japanese Rhino-conjunctivitis Quality of Life Questionnaire (JRQLQ No. 1). The changes in scores (difference from the pre-observation period) on the Nasal and Eye Symptom Questionnaire showed a dose-dependent reduction in rhinorrhea. In the safety evaluation, there were no significant differences in examinations of physiology, hematology, and blood biochemistry between the groups, and no adverse events attributable to the test foods were observed. These results suggest that intake of CJ peel powder can alleviate allergy-like symptoms.","PeriodicalId":401129,"journal":{"name":"Trends in Immunotherapy","volume":"35 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132386330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
A case of lichen planopilaris associated with lichen planus following Blaschko lines successfully treated with topical corticosteroid 扁平地衣伴扁平地衣的病例:Blaschko线成功治疗局部皮质类固醇
Trends in Immunotherapy Pub Date : 2021-12-09 DOI: 10.24294/ti.v5.i2.1363
Gülbin Yaşar Subaşı, Anıl Alpsoy, B. Ünal, E. Alpsoy
{"title":"A case of lichen planopilaris associated with lichen planus following Blaschko lines successfully treated with topical corticosteroid","authors":"Gülbin Yaşar Subaşı, Anıl Alpsoy, B. Ünal, E. Alpsoy","doi":"10.24294/ti.v5.i2.1363","DOIUrl":"https://doi.org/10.24294/ti.v5.i2.1363","url":null,"abstract":"Lichen planopilaris (LPP) is characterized by erythematous, keratotic follicular papules and cicatricial alopecia. LPP, the most common cause of cicatricial alopecia, is usually seen in women and causes significant psychosocial morbidity. We describe here a 42-year-old woman with a 6-month history of hair loss accompanied by itching on the scalp. Dermatological examination revealed patchy cicatricial alopecia in the vertex and band-like purple flat patches and plaques following the Blaschko lines on the right half of the body, together with post-inflammatory hyperpigmentation. Histopathological examination of the scalp biopsy was consistent with LPP, while thigh biopsy was consistent with lichen planus. With the histopathological and clinical evidence, our patient was evaluated as LPP associated with LP and successfully treated with topical corticosteroid. A few LPP and LP cases following the Blaschko lines have previously been reported separately. However, LPP, together with LP following Blaschko lines, have not been reported in the same patient.","PeriodicalId":401129,"journal":{"name":"Trends in Immunotherapy","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128745798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combination of anti-angiogenic therapy Apatinib and immune therapy potentiate tumor microenvironment 抗血管生成药物阿帕替尼联合免疫治疗增强肿瘤微环境
Trends in Immunotherapy Pub Date : 2021-11-26 DOI: 10.24294/ti.v5.i2.1.1376
Chunyi Gao, T. Hu
{"title":"Combination of anti-angiogenic therapy Apatinib and immune therapy potentiate tumor microenvironment","authors":"Chunyi Gao, T. Hu","doi":"10.24294/ti.v5.i2.1.1376","DOIUrl":"https://doi.org/10.24294/ti.v5.i2.1.1376","url":null,"abstract":"Tumor immune therapy, especially anti-programmed cell death ligand-1/programmed cell death-1 (PD-L1/PD-1) treatment, is currently the focus of substantial attention. However, despite its enormous successes, the overall response rate of cancer immunotherapy remains suboptimal. There is an increased interest in combining PD-L1/PD-1 treatment with anti-angiogenic drug Apatinib to enhance antitumor effect. Presently available data seem to suggest that Apatinib may exert immune suppressive effects to make the PD-L1/PD-1 treatment works. Here, we review the extensive tumor microenvironment immune modulatory effects from antiangiogenic agents Apatinib in order to supporting VEGFR2 targettherapies in clinical trials are existing.","PeriodicalId":401129,"journal":{"name":"Trends in Immunotherapy","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131624548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inflammaging in skin and intrinsic underlying factors 皮肤发炎及内在因素
Trends in Immunotherapy Pub Date : 2021-11-24 DOI: 10.24294/ti.v5.i2.1342
A. Aioi
{"title":"Inflammaging in skin and intrinsic underlying factors","authors":"A. Aioi","doi":"10.24294/ti.v5.i2.1342","DOIUrl":"https://doi.org/10.24294/ti.v5.i2.1342","url":null,"abstract":"Aging of organs starts from the time of birth and continues throughout life. Aging of skin can be divided into two distinct types—intrinsic aging and extrinsic, based on the fact that the skin is the outermost organ exposed to the external environment. However, despite their different histological features and triggers, intrinsic and extrinsic aging share common biochemical mechanisms. β-galactosidase, p16INK4a, and senescence-associated secretory phenotype (SASP) factors are detected in skin cells as biomarkers of senescence. In particular, inflammatory cytokines, the constituents of SASP, play pivotal roles in “inflammaging” which is a concept involving the relationship between aging and low-grade inflammation. In this review, the features of skin aging and its underlying mechanism of skin aging are summarized.","PeriodicalId":401129,"journal":{"name":"Trends in Immunotherapy","volume":"47 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126642368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信